Aclaris Therapeutics, Inc. 4
4 · Aclaris Therapeutics, Inc. · Filed Oct 13, 2015
Insider Transaction Report
Form 4
Tullman Stephen A.
Director
Transactions
- Conversion
Series C Preferred Stock
2015-10-13−17,437→ 0 total(indirect: By Trust)→ Common Stock (5,054 underlying) - Conversion
Common Stock
2015-10-13+46,188→ 394,014 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2015-10-13−110,000→ 0 total(indirect: By Trust)→ Common Stock (31,884 underlying) - Conversion
Series B Preferred Stock
2015-10-13−31,913→ 0 total(indirect: By Trust)→ Common Stock (9,250 underlying)
Holdings
- 521,739(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
- [F2]Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
- [F3]These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which Mr. Tullman's spouse serves as the trustee.
- [F4]These shares are held by NeXeption, LLC, of which Mr. Tullman is the Manager.